REGENXBIO Inc.
RGNX
$9.66
$0.293.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 1,589.64% | -78.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,589.64% | -78.93% | |||
| Cost of Revenue | -16.50% | 4.39% | |||
| Gross Profit | 182.06% | -76.18% | |||
| SG&A Expenses | 1.45% | -4.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -66.67% | -33.33% | |||
| Total Operating Expenses | -12.25% | 2.03% | |||
| Operating Income | 135.10% | -44.64% | |||
| Income Before Tax | 125.22% | -34.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 125.22% | -34.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 125.22% | -34.11% | |||
| EBIT | 135.10% | -44.64% | |||
| EBITDA | 141.53% | -47.87% | |||
| EPS Basic | 125.03% | -32.38% | |||
| Normalized Basic EPS | 125.03% | -32.38% | |||
| EPS Diluted | 124.99% | -32.56% | |||
| Normalized Diluted EPS | 124.94% | -32.38% | |||
| Average Basic Shares Outstanding | 0.75% | 1.31% | |||
| Average Diluted Shares Outstanding | 1.12% | 1.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||